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Abstract: Understanding the factors involved in the development of broadly neutralizing antibody
(bNAb) responses in natural infection can guide vaccine design aimed at eliciting protective bNAb
responses. Most of the studies to identify and study the development of bNAb responses have been
performed in individuals who had become infected via homo- or heterosexual HIV-1 transmission;
however, the prevalence and characteristics of bNAb responses in injecting drug users (IDUs) have
been underrepresented. We retrospectively studied the prevalence of bNAb responses in HIV-1
infected individuals in the Amsterdam Cohort, including 50 male and 35 female participants who
reported injecting drug use as the only risk factor. Our study revealed a significantly lower prevalence
of bNAb responses in females compared to males. Gender, transmission route and CD4+ count
at set point, but not viral load, were independently associated with the development of bNAb
responses in IDUs. To further explore the influences of gender in the setting of IDU, we also looked
into the Swiss 4.5k Screen. There we observed lower bNAb responses in female IDUs as well.
These results reveal that the emergence of bNAbs may be dependent on multiple factors, including
gender. Therefore, the effect of gender on the development of bNAb responses is a factor that should
be taken into account when designing vaccine efficacy trials.
Keywords: HIV-1; transmission route; injecting drug users; broadly neutralizing antibodies; gender
1. Introduction
An effective HIV-1 vaccine should be capable of eliciting broadly neutralizing antibodies (bNAbs),
defined as the ability to neutralize various heterologous viruses from different subtypes, in order to
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provide protection against HIV-1 acquisition [1–3]. During HIV-1 infection, neutralizing antibodies
(NAbs) develop within the first three months of infection [4,5]. However, these NAbs are usually
strain-specific and the autologous virus can rapidly escape from them. bNAbs develop within
1–3 years post-seroconversion (post-SC), but only in about 10–30% of HIV-1 infected individuals [6–17].
Approximately 1% of the HIV-1 infected individuals, termed “elite neutralizers”, develop bNAbs
that neutralize the majority of HIV-1 subtypes with very high breadth and potency [8,9,12,14,15].
Although bNAbs do not protect from disease progression, the passive transfer of bNAbs can
completely block infection by a chimeric simian–human immunodeficiency virus (SHIV) in nonhuman
primate studies [18–24] and reduce viral load in chronically infected humans and macaques [25–29].
The presence of bNAbs in humans indicates that there are no fundamental immunological barriers to
prevent their induction, lending further support to the search for a vaccine that induces bNAbs.
The most predictable clinical markers for the development of bNAbs are duration of infection,
high viral load, and in some cohorts low CD4+ T cell count [6,7,11,14–17,30,31]. Furthermore, circulatory
follicular helper CD4+ T cells (Tfh cells) [32], as well as HIV-specific Tfh cells in the lymph and some
human leukocyte antigen (HLA) class II alleles are associated with bNAb development [33,34].
Virological markers such as viral diversity, HIV-1 subtype, antibody effector functions, IgG-subclass
and particular envelope glycoprotein (Env) characteristics are also suggested to be potential contributors
to the development of neutralization breadth [12,15,35–38]. On the other hand, history of antiretroviral
use, age, and transmission route did not correlate with the development of bNAbs in previous
studies [11,15,39]. Interestingly, in the Swiss 4.5K Screen Rusert et al. [15] found a positive correlation
for duration of infection and black ethnicity with the development of bNAbs.
Most of the studies to identify bNAb responses were performed in individuals who were
infected via homo- (men who have sex with men, MSM) or heterosexual HIV-1 transmission.
The determinants of bNAb induction in injecting drug users (IDUs) remains underrepresented, while the
immunomodulatory effect of drug use [40–43] and the higher risk of multiple virus transmissions may
influence the development of bNAbs [38]. Here, we studied the prevalence and potency of bNAb
responses in a mixed-gender cohort of HIV-1 infected individuals who reported injecting drug use as
their only HIV-1 risk factor. The data were compared to similar data obtained from MSM participants
of the Amsterdam Cohort [6,31,39], as well as MSM and IDU of the Swiss 4.5K Screen [15].
2. Materials and Methods
2.1. Ethics Statement
The Amsterdam Cohort Studies on HIV-1 infection and AIDS (Amsterdam Cohort) are being
conducted in accordance with the ethical principles set out in the declaration of Helsinki, and all
participants provided written informed consent. The study was approved by the institutional Medical
Ethics Committee of the Academic Medical Center, University of Amsterdam.
Data from the Swiss 4.5 Screen integrated as a comparison group in the current study comprised
solely the re-analysis of previously generated data [15,38]. Ethical approval from the Swiss HIV Cohort
Study (SHCS) and the Zurich Primary HIV Infection Study and written informed consent from all
participants has been obtained as detailed in [15].
2.2. Study Population and Phenotype
We screened serum samples from participants of the Amsterdam Cohort for the presence of
bNAb responses. The study population consisted of a total of 299 HIV-1 infected MSM [39,44] and 85
HIV-1 infected IDUs (50 men and 35 women) [45,46]. Participants were eligible to participate in this
study when they were therapy-naïve and when a serum sample was available ~3 years post imputed
or documented date of seroconversion (SC), when bNAb activity commonly peaks [6–8,10,11,14,17].
For MSM, this was on average 34 months (range, 21–37 months) and for IDUs, on average 36 months
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(range, 23–55 months). A total of 1380 MSM and 672 IDU, of which 243 were female, were selected
from the Swiss 4.5 Screen, established as previously described [15,38].
2.3. Neutralization Assays
Sera were tested for bNAb responses in a pseudovirus assay involving six tier-2 viruses
(JRCSF, 92BR020, 93IN905, 92TH021, 94UG103 and MGRMC026) in a single round of viral infection
developed by Monogram Biosciences. This six-virus panel covered 93% of the variation in neutralization
of a larger pseudovirus panel (n = 15) [8]. For each individual, we calculated the geometric mean
ID50 titer (GMT) across the six-virus panel. Data on HIV-1 neutralizing activity in sera of MSM
were available from our previous studies [6,31,39], and control sera were measured in each assay for
comparability. Neutralization breadth in the Swiss 4.5k Screen was measured against an eight-virus
multi-clade panel in a pseudovirus assay on TZM-bl cells as previously described [15,38].
2.4. Statistical Analysis
Differences between groups were analyzed with a Mann–Whitney test. Mann–Whitney tests
and Spearman correlation tests were performed in GraphPad prism 7 (GraphPad Software, La Jolla,
California, USA). A univariate and multivariate regression analysis on both the IDU and MSM cohort
was performed using SPSS with the logarithmic transformed GMT as dependent factor and mode of
transmission, gender, viral load at setpoint, and CD4+ T cell count at setpoint as potential predictors.
Mode of transmission and gender were grouped as MSM male, IDU male and IDU female. As the MSM
cohort did not include females, gender and mode of transport could not be separated as independent
variables. The effect of bNAb responses on disease progression was analyzed in a Kaplan–Meier and
Cox proportional hazard analysis using clinical AIDS (1993 CDC definition) as an endpoint. Individuals
were divided into 3 groups: those who neutralized ≤ 1; 2 or 3; or ≥ 4 viruses at an ID50 titer ≥ 100.
Left truncation of follow-up time was performed for the time between the imputed SC date and first
seropositive visit using S-Plus 8 (Insightful Corporation, Seattle, Washington, USA). P-values < 0.05
were considered significant.
In order to determine the effect of IDU-transmission route on bNAb activity amongst participants
in the Swiss 4.5 k Screen, we used uni- and multivariable Tobit regression models with the neutralization
score determined previously [15] as an outcome variable. These models are appropriate for the
neutralization score data since they consider the truncated nature of these scores. In analogy to the studies
using the Amsterdam Cohort, we focused in this analysis on MSM and IDUs (i.e., other transmission
groups were excluded). Since the vast majority of MSM and IDUs in the SHCS from which Swiss 4.5K
Screen participants were selected are of white ethnicity (93.3%) and infected with subtype B (92.5%),
we restricted this analysis to individuals of white ethnicity infected with subtype B. The multivariable
model was adjusted for duration of infection, viral load, and CD4+ T cell count as these variables were
found to be associated with neutralization breadth by Rusert et al. [15].
2.5. Diversity Analysis
The HIV-1 envelope gp160 gene (env) was PCR amplified from DNA isolated from PBMCs that
were infected in vitro with a single clonal HIV-variant and subsequently sequenced as described
previously [47]. Nucleotide sequences were aligned using ClustalW in the software package of
BioEdit. Nucleotide diversity within each individual was calculated for 23 MSM and 15 IDU infected
individuals with median GMTs of 64 (range 20–782) and 47 (range 23–978), respectively, with the
Kimura-2 parameter substitution model in the software package MEGA 6. The selection of 23 MSM
and 15 IDU infected individuals was made on the basis that env sequences from within the first year
post-SC from these individuals were available. To assess if multiple virus transmission (MVT) has
occurred in the IDU and MSM, we analyzed the earliest available env sequences, within 3 months of
SC (MSM = 8 and IDU = 5), as previously described [48–51].
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3. Results
3.1. Broadly Neutralizing Antibody Responses in Injecting Drug Users
The prevalence and potency of bNAb responses was determined in the IDU participants of the
Amsterdam Cohort (n = 85) and compared with the MSM participants of the Amsterdam Cohort
(n = 299; previously determined [6,31,39]) (Figure 1 and Supplementary Table S1) analyzed against
the same virus panel. The potency of the bNAb responses of all participants was defined by the
geometric mean titer (GMT) values across the six-virus panel and was strongly correlated with both
the number of viruses neutralized (Spearman r = 0.85, P < 0.001) as well as the number of viruses
that were neutralized with neutralization titers > 100 (Spearman r = 0.92, p < 0.001). Of the 384 HIV-1
infected individuals (IDU and MSM combined), 25% developed bNAb responses, defined by their
ability to neutralize ≥ 4 viruses of the six-virus panel, at ID50 titers > 100. The prevalence of bNAbs
in the IDUs was lower compared to the prevalence in the MSM (19% and 27%, respectively; Table 1).
Furthermore, the bNAb responses in IDUs were weaker as they had significantly lower GMT values
compared to MSM (p = 0.0009) (Figure 1A). The IDUs showed an abnormal distribution of GMT values,
with a number of outliers at the top of the range (median GMT = 41 (range 20–978)), whereas the MSM
had a more normal distribution of the GMT values (median GMT = 68 (range 20–782)). Interestingly,
the IDUs had significantly more elite neutralizers (GMT > 500) compared to the MSM (3.5% and 0.3%,
respectively; p = 0.035, Fisher’s exact test) (Table 1).
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Figure 1. The potency of broadly neutralizing antibodies (bNAb) in the HIV-1 infected men who have sex
with men (MSM) and injecting drug user (IDU) p rticipants of the Amsterdam Cohort. Serum samples
from MSM (n = 299) and IDUs (n = 85) from the Amsterdam Cohort Studies on HIV-1 infection and AIDS
(ACS) w re screened for the capability to neutralize six viruses from different HIV-1. (A) Comparison of
bNAb responses in MSM (gray data points) and IDUs (black data points). Each data point represents
one individual’s geometric mea ID50 titer (GMT) across the six-virus panel. (B) Same as A, but with the
IDU separated i men (square) and women (t iangl ). Each data point represent on indi idual’s GMT.
Statistically significant differ nces between the differe t cohorts were determined using a M nn–Whitney
t-test and the respective P-v ues are shown. Horizontal bars represent the median values per group.
As the IDU participants are a mixed-gender population, we repeated our analyses after the
exclusion of women (n = 35), which allowed a comparison of exclusively men of both the IDUs
(n = 50) and MSM (n = 299) (Figure 1B). After the exclusion of women, the difference in GMT and
pr valence of bNAb responses between the two horts faded (p = 0.1126). This sugges ed that the
female gender contributed to the differences between the IDU and MSM in the Amsterdam Cohort.
Therefore, we compared the GMT values between all the men (n = 349) and women (n = 35), irrespective
of the route of HIV-1 transmission. HIV-1 infected men had higher GMT values than HIV-1 infected
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women (p = 0.0005). A similar trend was observed within the IDU cohort (Figure 1B) (p = 0.0593);
however, this was not statistically significant, most likely due to the low number of participants per
group. Furthermore, male IDUs were more frequently classified as elite neutralizers than female IDUs
(3/50 or 6% versus 0/35 or 0%, respectively; Table 1).
Table 1. Prevalence of broadly neutralizing antibody responses in HIV-1 infected MSM and IDUs.
N % Individuals with bNAb Responses (≥ 4Viruses Neutralized with IC50 > 100)
% Elite Neutralizers
(GMT > 500)
MSM 299 27% p = 0.1567 0.3% p = 0.0354
IDU 85 19% 3.5%
IDU-Male 50 20% p = 0.7839 6.0% p = 0.2647
IDU-Female 35 17% 0.0%
3.2. Clinical Factors Associated with the Development of Broadly Neutralizing Antibody Responses
Duration of infection was shown to be a very important predictor for bNAb development. In our
study, we included patients and samples based on similar time points post-SC (~3 years post-SC),
and therefore we did not observe a correlation between duration of infection and GMT. In addition to
duration of infection, high viral load and low CD4+ T cell count were the strongest predictors for the
development of bNAb responses in previous studies [6,7,11,14–17,31,33]. We analyzed the association
between the CD4+ T cell count and the viral load at setpoint and the development of bNAbs within the
MSM and the IDU participants. We observed that within the IDUs, women had higher mean CD4+ T cell
counts, although not significantly higher than the MSM, while the viral load at setpoint was not statistically
different between men and women in the IDUs (Figure 2A,B). In line with this, in the combined MSM
and IDU, we observed a negative correlation between the CD4+ T cell count at setpoint (approximately
18 months post-SC) (Spearman r = −0.20, p < 0.001), and a positive correlation between the viral load
at setpoint, and the development of bNAbs (Spearman r = 0.11, p = 0.031). These correlations were
stronger when only the MSM were analyzed (Spearman r = −0.24, p < 0.001 for CD4+ T cell count;
Spearman r = 0.14, p = 0.014 for viral load). Conversely, in the IDUs, a similar trend was observed
between the CD4+ T cell count at setpoint and bNAb responses (Spearman r = −0.20, p = 0.133), while no
correlation with viral load at setpoint was observed, which could be due to the low number of participants.
To determine whether these parameters were independently associated with the development of bNAb
responses, we performed a multivariate model analysis on the combined IDU and MSM cohorts using all
parameters as covariates (Table 2). As the MSM consisted of males only, precluding the evaluation of the
mode of transmission as an independent variable, we combined the variables of gender and transmission
into the following groups: MSM, male IDU and female IDU. In the multivariate model, the viral load at
setpoint was no longer independently associated with bNAb development. However, low CD4+ T cell
count at setpoint and male gender combined with mode of transmission were still associated with the
development of bNAbs (p = 0.017 and p = 0.001, respectively).
Table 2. Factors associated with the development of broadly neutralizing antibodies in participants of
the Amsterdam Cohort.
Univariate Analysis Multivariate Analysis*
p-Value Effect p-Value Effect
Gender and route of transmission 0.002 −0.16 0.001 −0.12
CD4+ T cell count at setpoint 0.002 −0.16 0.017 −0.13
Viral load at setpoint 0.011 1.34 0.127 0.09
* The multivariable model was adjusted for the variables shown in the table.
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bNAb responses generally have no effect on disease progression [6,52]. Consistent with these
reports, we found that individuals in the IDU cohort that could neutralize the majority of the viruses (≥4)
at ID50 titers higher than 100 (n = 16) had a similar time to AIDS compared to IDU with intermediate
NAb breadth (neutralizing 2 or 3 viruses, n = 24) or those with no bNAb responses (neutr lizing 1 or
none of the six viruses, n = 45). The results indicate that bNAbs in IDUs also had no beneficial effect
on the clinical course of infection, similar to bNAbs in individuals who were infected via (MSM) or
heterosexual transmission [6,16,31,36].
Viral diversity has been shown to correlate with the development of bNAb responses [15,36].
Therefore, we performed a variety of approaches to assess whether early sequence diversity,
including multiple virus transmission (MVT), was linked to bNAb development. We did not
observe any correlation between the presence of bNAbs and the env diversity in these individuals.
However, we found that the sequence diversity of viruses isolated within the first three months post-SC
may be higher in the IDUs compared to the MSM. Although the numbers of individuals eligible for
inclusion in these analyses was small and the trend did not reach statistical significance (P = 0.0932),
it may point at possible MVT in (some of) the IDUs (Figure 2C). Interestingly, four out of five IDU
and only one out of eight MSM displayed high env diversity (>0.01) and demonstrated phylogenetic
evidence of MVT (p = 0.022). Nevertheless, we could not find significant evidence for an association
between viral diversity and bNAb development. However, we note that the number of individuals for
which early env sequences were available and the number of sequences per timepoint were too small
to study this reliably.
3.3. Broadly Neutralizing Antibody Responses in the Swiss 4.5K Screen
Previous studies on clinical variables associated with the development of bNAb responses
did not show a strong association with the gender of the infected individual [8,11,14,15,53–56].
A lower frequency of neutralization breadth was, however, detected amongst females in the Swiss
4.5k Screen [15,38]. To further explore the influences of gender in the setting of IDU, we therefore
re-analyzed the neutralization data of 1380 MSM and 672 IDU, of which 243 were female, established
by Rusert et al. [15]. The direct comparison of MSM, male and female IDU (Table 3), analogous to the
analysis of the Amsterdam Cohort (Table 2), showed that also in the Swiss 4.5K Screen, female IDUs had
significantly lower neutralization scores than male IDUs. Notably, in contrast to the Amsterdam Cohort,
IDUs showed higher breadth compared to MSM. This highlights that IDU status is linked with positive
and female gender with negative drivers of neutralization breadth in the Swiss 4.5K Screen. While we
observed a significant negative association between CD4+ T cell count and neutralization score in the
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univariable model (Table 3), the effect was lost in the multivariable model, likely reflecting the inverse
relationship between CD4 cell numbers and viral load in the Swiss 4.5K Screen. Finally, we observed
that neutralization scores were strongly and significantly associated with both infection time and
virus load (Table 2), which is in line with previous studies [8,11,14,15,53–56]. Time of infection was
not a factor in the Amsterdam Cohort dataset, because samples were included on very similar time
post-SC (~3 years post-SC). Overall, these data confirm the lower neutralization breadth in female IDU
compared to male IDU observed in the Amsterdam Cohort.
Table 3. Factors associated with the presence of broadly neutralizing antibodies in participants of the
Swiss 4.5k Screen.
Univariable Analysis Multivariable Analysis
p-Value Effect p-Value Effect
Risk Group and
Sex
MSM 1.5 × 10−5 −1.16 0.004 −0.77
IDU-Male reference reference
IDU-Female 0.007 −1.06 0.006 −1.04
CD4+ T cell count 0.005 −0.31 0.100 −0.19
Viral load 0.019 0.33 4.5 × 10−4 0.51
Infection Time Group 1 reference reference
Group 3 2.3 × 10−26 3.40 2.8 × 10−27 3.44
Group 5 3.1 × 10−33 3.72 2.1 × 10−32 3.76
Data reanalyzed from Rusert et al. [15]. The value “reference” shows that this group was used for comparison with
the other groups. Group 1, low bNAb score; group 3, intermediate bNAb score; group 5, high bNAb score. The
multivariable model was adjusted for the variables shown in the table.
4. Discussion
We found that individuals in the Amsterdam Cohort infected with HIV-1 via contaminated needles
generally had lower bNAb titers compared to HIV-1 infected MSM. This finding was not related to the
calendar period in which the participants were infected or the subtype with which they were infected,
because the MSM and IDU participants of the Amsterdam Cohort are similar in both respects (infection
between 1982 and 1997 and exclusive infection with subtype B for both MSM and IDUs). Moreover, no
significant differences in age, disease course, ethnicity and viral loads were observed between the IDU
and MSM participants, which could explain the difference in bNAb development between these two
groups. Interestingly, this difference appears to be independently associated with female gender in the
IDU group, with females having lower bNAb responses compared to male IDUs. Previous studies
have not observed such a difference when male versus female heterosexual HIV-1 transmission was
studied [6,11,16,17,31]. These studies were conducted on different subgroups and at different infection
times; however, in one study, the frequency of antibody breadth was lower in females [15].
The most predictable clinical markers for the development of bNAbs observed in previous studies
are a high viral load and a reduced CD4+ T cell count [6,11,16,17,31]. Interestingly, one study showed
that both IDUs and women in general have a higher CD4+ T cell count at SC compared to MSM [57],
which have been shown to be predictors of lower bNAb responses. In our current study, the overall
CD4+ T cell count and viral load at setpoint of the Amsterdam MSM and IDU participants were similar
and confirmed to be correlated with the development of bNAb responses. Moreover, CD4+ T cell count
at setpoint and combined gender and transmission route, but not viral load at setpoint, predicted the
presence of bNAb in the multivariate analysis. Interestingly, within the Amsterdam IDU participants,
we observed higher CD4+ T cell counts for women compared to men, which could be correlated to the
lower bNAb responses observed in female IDUs. However, the CD4+ T cell counts for the female IDUs
were similar to the MSM CD4+ T cell count at setpoint, contradicting the idea that CD4+ T cell count
is the most important marker for bNAb development. Also, because CD4+ T cell count at setpoint,
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combined gender and transmission route and viral load at setpoint were all independently associated
with bNAbs, the development of bNAbs remains multifactorial.
In the Swiss 4.5K Screen, female IDUs had significantly lower neutralization scores than male
IDUs, who displayed higher neutralization activity than MSM, suggesting a positive influence of the
IDU status in men but not women on bNAb development. A higher neutralization activity amongst
male IDUs was not observed in the Amsterdam Cohort. The differences in bNAb responses between
MSM and male IDU within the two cohorts, strengthen the observation that female gender was
the strongest association for lower bNAb responses. Notably, in contrast to the Amsterdam Cohort,
no strong effect of CD4+ T cell counts on bNAb activity were seen in the Swiss 4.5K Screen, as the
negative association of CD4 cell counts with bNAb responses was lost in multivariable testing. Some of
these individual differences may be in part due to differential cohort size and design. For instance, as
the Swiss 4.5K screen recruited individuals at different stages of the infection, whereas the Amsterdam
IDU cohort was selected from a narrower range, the predictive capacity of CD4 and viral load may
differ. Despite the individual differences, the two cohorts strengthen the key observation that female
IDUs have lower bNAb responses compared to male IDUs, indicating that there is a fundamental
difference in bNAb development between male and female IDU. Interestingly, in most previous studies,
this gender bias was not observed in women with heterosexual transmission [8,11,14,53–56].
Recreational drugs can have various immune-modulating properties depending on the frequency
of use and type of drug used [41,42]. For example, it has been suggested that endogenous opioids can
suppress B cell proliferation [43]. How this might influence bNAb development and whether drugs
might have differential effects in males and females is unknown. In addition, we could not exclude
any cofounder effects of alcohol or other polysubstance use, as this was not systematically recorded in
the cohorts. Interestingly, it has been observed that, in general, women elicit higher antibody titers to
infections and vaccinations [58]. However, lower antibody titers were also observed in non-human
primates after HIV-1 protein vaccination [59], and it was observed that females had a lower frequency
of breadth [15,38], which agrees with the observed findings in this study and could have been enhanced
by the drug use.
Viral diversity within the first year of infection, another proposed marker for bNAb development,
did not correlate with bNAb development. Interestingly, despite the lower overall prevalence of bNAb
responses in the IDU group, more elite neutralizers were found in this group, with 6% of male IDUs
qualifying as elite neutralizers compared to only 0.3% of MSM and 0% of female IDUs. When we
analyzed the viral diversity of samples obtained in the first three months post-SC, we did find that all
but one IDU demonstrated evidence consistent with a pattern associated with MVT. These findings
are in concordance with other studies in which MVT has been observed in up to 60% of the IDU
individuals [60,61]. Interestingly, the MSM elite neutralizer was the only MSM predicted to have
MVT, suggesting that MVT might have contributed to the high level of bNAbs in this individual.
The effect of very diverse sequences—for example, superinfection—on bNAb development is also still
unclear, with some studies suggesting that superinfection might increase neutralization breadth [62,63],
whereas others observed no such increase [54,64]. These conflicting results suggest that the role of
viral diversity in the induction of bNAbs is probably a co-dependency factor.
5. Conclusions
In conclusion, we found that women infected with HIV-1 using contaminated needles developed
bNAb responses less efficiently than men that attracted HIV-1 via the same transmission route.
This difference is most likely multifactorial, where early viral diversity caused by multivariant
transmission, CD4+ T cell count, viral load and drug use may all play a role. Therefore, the effect of
gender on the development of bNAb responses is a factor that should be considered when designing
vaccine efficacy trials.
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